133 DH domain-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Organohalogen compounds | 1 | 0.0 | 89× | not tested | |
| Organic nitrogen compounds | 1 | 0.1 | 7.95× | not tested | |
| Organoheterocyclic compounds | 3 | 0.6 | 4.94× | not tested | |
| Benzenoids | 1 | 0.3 | 3.47× | not tested | |
| Organic acids and derivatives | 1 | 0.6 | 1.64× | not tested | |
| Nucleosides, nucleotides, and analogues | 1 | 1.1 | 0.92× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02031 | THG | (6S)-5,6,7,8-tetrahydrofolic acid | 2 |
| DB00116 | — | — | 1 |
| DB00142 | — | Glutamic acid | 1 |
| DB03247 | FMN | Flavin mononucleotide | 1 |
| DB03256 | — | (6R)-Folinic acid | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| UNX | UNKNOWN ATOM OR ION | 3 |
| LXA | ~{N}-(1~{H}-benzimidazol-2-ylmethyl)-2-methoxy-ethanamide | 2 |
| THG | (6S)-5,6,7,8-TETRAHYDROFOLATE | 2 |
| 60P | 3-methylthiophene-2-carboxylic acid | 1 |
| 9JY | (2S)-3-[(3S)-1-(ethylsulfonyl)piperidin-3-yl]-2-{[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino}propan-1-ol | 1 |
| 9K1 | (2S)-2-{[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino}-3-(pyridin-3-yl)propan-1-ol | 1 |
| KLU | (2S)-4-(chloroacetyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxamide | 1 |
| LFO | N,1-dimethyl-1H-indole-3-carboxamide | 1 |
| O2A | N-methyl-1H-indole-7-carboxamide | 1 |
| RWS | 1-(5-methyl-1,3,4-thiadiazol-2-yl)piperidine | 1 |
| T7Y | N-[3-(2-oxopyrrolidin-1-yl)phenyl]acetamide | 1 |
| UWS | 6-methyl-2-[(3-methyl-1,2-oxazol-5-yl)methyl]pyridazin-3(2H)-one | 1 |
| VW7 | N-(8-methyl-1,2,3,4-tetrahydroquinolin-5-yl)acetamide | 1 |
| W0Y | N-methyl-4-sulfamoylbenzamide | 1 |
| WJ7 | 2-bromo-4-fluoro-N,N-dimethylbenzamide | 1 |
| WKY | N-(3-methylpyridin-4-yl)acetamide | 1 |
| YXB | N-[(1H-indol-4-yl)methyl]ethanamine | 1 |
| YXH | 1-(1H-benzimidazol-2-yl)methanamine | 1 |
| YXU | 5-methoxy-1H-pyrrolo[3,2-b]pyridine | 1 |
| YXY | 4,4-difluorocyclohexane-1-carboxamide | 1 |